drugset / Trial / NCT03463161
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to determine response rate of the combination of pembrolizumab plus epacadostat in patients with head and neck cancers that have received prior immunotherapy.
Timeline
- Start
- 2018-03-23
- Primary completion
- 2018-12-04
- Completion
- 2018-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | 100 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg/kg | Intravenous |